Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

44.94 -1.48 (-3.19%)
Streaming Delayed Price Updated: 3:11 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton (ETON) Q1 2026 Earnings Call Transcript ↗
Eton (ETON) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Eton Pharmaceuticals (NASDAQ:ETON) Soars on Q1 Beat, Raises Full-Year Guidance ↗
Via Chartmill
Eton Pharmaceuticals (NASDAQ:ETON) Posts Mixed Q4 2025 Results with Revenue Beat and EPS Miss ↗
Via Chartmill
News headline image
Eton Pharmaceuticals Q1 Earnings Call Highlights ↗
Eton Pharmaceuticals (NASDAQ:ETON) raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and... 
Via MarketBeat
Topics Earnings
News headline image
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
-- Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease -- 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces CFO Succession Plan
Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharma (ETON) Earnings Call Transcript ↗
Eton Pharma (ETON) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharma (ETON) Q3 2025 Earnings Transcript ↗
Eton Pharma (ETON) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
ETON PHARMACEUTICALS INC (NASDAQ:ETON) Reports Q3 2025 Revenue Beat and EPS Miss ↗
Eton Pharmaceuticals Q3 2025 results: A mixed quarter with a 7.6% revenue beat but a miss on earnings per share. 
Via Chartmill
News headline image
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton (ETON) Q2 Revenue Jumps 108% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.